Equillium Shares Ride Higher After Positive Data From Lead Asset In Kidney Inflammation

Loading...
Loading...
  • Equillium Inc EQ has announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab in patients with lupus nephritis (LN).
  • The interim data from the LN portion of the EQUALISE study showed compelling responses in a patient population with significantly greater baseline proteinuria than in recent studies, with a mean baseline urine protein creatinine ratio (UPCR) of 5.8 grams, the company said.
  • Also Read: Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal.
  • At the end of the study, 83% of patients achieved a complete or partial clinical response, with 67% reaching a greater than 80% reduction in UPCR. 
  • 8 of 12 (67%) subjects achieved over 50% reduction in UPCR (6 subjects still dosing).
  • The company continues to enroll patients in the Type B portion of the EQUALISE study and anticipates sharing topline data in mid-2023. 
  • Itolizumab was generally safe and well tolerated, with no drug-related serious adverse events or treatment discontinuations.
  • Price Action: EQ shares are up 21.8% at $2.35 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...